Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: Synthesis, biological properties, and antinociceptive activities

Journal of Medicinal Chemistry

Volumn 43, Issue 7, 2000, Pages 1398-1408

  Chen, Huixiong ^a   Noble, Florence ^a   Mothé, Aurélie ^a   Meudal, Hervé ^a   Coric, Pascale ^a   Danascimento, Sophie ^a   Roques, Bernard P ^a   George, Pascal ^b   Fournié Zaluski, Marie Claude ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINOCICEPTIVE AGENT; PHOSPHINIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HOT PLATE TEST; MALE; MOUSE; NONHUMAN;

ANALGESICS; ANIMALS; ANTIGENS, CD13; ASPARTIC ENDOPEPTIDASES; ENKEPHALINS; ENZYME INHIBITORS; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; MAGNETIC RESONANCE SPECTROSCOPY; METALLOENDOPEPTIDASES; MICE; MOLECULAR CONFORMATION; NEPRILYSIN; PAIN MEASUREMENT; PHOSPHINIC ACIDS; RENIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034611594     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990483l     Document Type: Article

References (43)

1. Herz, A. Opioids. Handbook Exp. Pharmacol. 1993, 104, I and II.
2. Chaillet, P.; Coulaud, A.; Zajac, J. M.; Fournié-Zaluski, M. C.; Costentin, J.; Roques, B. P. The mu rather than the delta subtype of opioid receptors appears to be involved in enkephalin induced analgesia. Eur. J. Pharmacol. 1984, 101, 83-90.
3. Matthes, H. W. D.; Maldonado, R.; Simonin, F.; Valverde, O.; Slowe, S.; Kitchen, I.; Befort, K.; Dierich, A.; Le Meur, M.; Dolle, P.; Tzavara, E.; Hanoune, J.; Roques, B. P.; Kieffer, B. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature 1996, 383, 819-823.
4. König, M.; Zimmer, A. M.; Steiner, H.; Holmes, P. V.; Crawley, J. N.; Brownstein, M. J.; Zimmer, A. Pain responses, anxiety and agression in mice deficient in pre-proenkephalin. Nature 1996, 383, 535-538.
5. Roques, B. P.; Noble, F.; Daugé, V.; Fournié-Zaluski, M. C.; Beaumont, A. Neutral endopeptidase 24.11. Structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 1993, 45, 87-146.
6. Roques, B. P.; Fournié-Zaluski, M. C.; Soroca, E.; Lecomte, J. M.; Malfroy, B.; Llorens, C.; Schwartz, J. C. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 1980, 288, 286-288.
7. Fournié-Zaluski, M. C.; Chaillet, P.; Bouboutou, R.; Coulaud, A.; Chérot, P.; Waksman, G.; Costentin, J.; Roques, B. P. Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes. Eur. J. Pharmacol. 1984, 102, 525-528.
8. Schmidt, C.; Peyroux, J.; Noble, F.; Fournié-Zaluski, M. C.; Roques, B. P. Analgesic responses elicited by endogenous enkephalins (protected by mixed peptidase inhibitors) in a variety of morphine-sensitive noxious tests. Eur. J. Pharmacol. 1991, 192, 253-262.
9. Noble, F.; Soleilhac, J. M.; Soroca, E.; Turcaud, S.; Fournié-Zaluski, M. C.; Roques, B. P. Inhibition of the enkephalin metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induced potent analgesic responses in mice and rats. J. Pharmacol. Exp. Ther. 1992, 261, 181-190.
10. Luciani, N.; Marie-Claire, C.; Ruffet, E.; Beaumont, A.; Roques, B. P.; Fournié-Zaluski, M. C. Characterization of Glu350 as a critical residue involved in the N-terminal amine binding site of aminopeptidase N (EC 3.4.11.2): Insights into its mechanism of action. Biochemistry 1998, 37, 686-692.
11. Bateman, R. C.; Jackson, D.; Slaughter, C. A.; Unnithan, S.; Chai, Y. G.; Moomaw, C.; Hersh, L. B. Identification of the active site arginine in rat neutral endopeptidase 24.11 (enkephalinase) as arginine 102 and analysis of a glutamine 102 mutant. J. Biol. Chem. 1989, 264, 6151-6157.
12. Chen, H.; Roques, B. P.; Fournié-Zaluski, M. C. Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1511-1516.
13. Chen, H.; Noble, F.; Coric, P.; Fournié-Zaluski, M. C.; Roques, B. P. Aminophosphinic inhibitors as transition state analogues of enkephalin-degrading enzymes: A class of central analgesics. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12028-12033.
14. Matthews, B. W. Structural basis of the action of thermolysin and related zinc peptidases. Acc. Chem. Res. 1988, 21, 333-340.
15. Berger, J. A novel approach to analgesia: Synthesis and structure-activity relationships of some potent and selective inhibitors of enkephalinase A. 19th National Medicinal Chemistry Symposium, Tucson, AZ, 1984.
16. Gomez-Monterrey, I.; Turcaud, S.; Lucas, E.; Bruetschy, L.; Roques, B. P.; Fournié-Zaluski, M. C. Exploration of neutral endopeptidase active site by a series of new thiol-containing inhibitors. J. Med. Chem. 1993, 36, 87-94.
17. Baylis, E. K.; Campbell, C. D.; Dingwall, J. G. 1-aminoalkylphosphonous acids. Part 1. Isosteres of the protein amino acids. J. Chem. Soc., Perkin Trans, 1 1984, 2845-2853.
18. 1H NMR configuration correlation for retro-inverso dipeptides: Application to the determination of the absolute configuration of "enkephalinase" inhibitors. Relationships between stereo-chemistry and enzyme recognition. J. Med. Chem. 1986, 29, 751-757.
19. Roques, B. P. Zinc metallopeptidases: Active site structure and design of selective and mixed inhibitors - new approaches in the search for analgesics and antihypertensives. Biochemical Society Transactions; Portland Press: London, 1993; Vol. 21, pp 678-685.
20. Fournié-Zaluski, M. C.; Lucas, E.; Waksman, G.; Roques, B. P. Differences in the structural requirements for selective interaction with neutral metalloendopeptidase (enkephalinase) or angiotensin converting enzyme. Molecular investigation by use of new thiol inhibitors. Eur. J. Biochem. 1984, 139, 267-274.
21. Fournié-Zaluski, M. C.; Coric, P.; Turcaud, S.; Bruetschy, L.; Lucas, E.; Noble, F.; Roques, B. P. Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation. J. Med. Chem. 1992, 35, 1259-1266.
22. Rupreht, J.; Ukponmwan, O. E.; Admiral, P. V.; Dzolzic, M. R. Effect of phosphoramidon - a selective enkephalinase inhibitor on nociception and behaviour. Neurosci. Lett. 1983, 41, 331-335
23. Altstein, M.; Blumberg, S.; Vogel, Z. Phosphoryl-Leu-Phe: A potent inhibitor of the degradation of enkephalin by enkephalinase. Eur. J. Pharmacol. 1981, 76, 299-300.
24. Elliot, R. L.; Marks, N.; Berg, M. J.; Portoghese, P. S. Synthesis and biological evaluation of phosphoramidate peptide inhibitors of enkephalinase and angiotensin-converting enzyme. J. Med. Chem. 1985, 28, 1208-1216.
25. De Lombaert, S.; Erion, M. D.; Tan, J.; Blanchard, L.; ElChehabi, L.; Ghai, R. D.; Sakane, Y.; Berry, C.; Trapani, A. J. N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors. J. Med. Chem. 1994, 37, 498-511.
26. Tiraboschi, G.; Jullian, N.; Théry, V.; Antonczak, S.; Fournié-Zaluski, M. C.; Roques, B. P. A Three-dimensional construction of the active site (region 507-749) of human neutral endopeptidase (EC 3.4.24.11). Protein Eng. 1999, 12, 141-149.
27. Chackalamannil, S.; Chung, S.; Stamford, A. W.; McKittrick, B. A.; Wang, Y.; Tsai, H.; Cleven, R.; Fawzi, A.; Czarniecki, M. Highly potent and selective inhibitors of endothelin converting enzyme. Bioorg. Med. Chem. Lett. 1996, 6, 1257-1260.
28. McKittrick, B. A.; Stamford, A. W.; Weng, X.; Ma, K.; Chackalamannil, S.; Czarniecki, M.; Cleven, R. M.; Fawzi, A. B. Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11. Bioorg. Med. Chem. Lett. 1996, 6, 1629-1634.
29. Krapcho, J.; Turk, C.; Cushman, D. W.; Powell, J. R.; DeForest, J. M.; Spitzmiller, E. R.; Karanewsky, D. S.; Duggan, M.; Rovnyak, G.; Schwartz, J.; Natarajan, S.; Godfrey, J. D.; Ryono, D. E.; Neubeck, R.; Atwal, K. S.; Petrillo, E. W., Jr. Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines. J. Med. Chem. 1988, 31, 1148-1160.
30. Patchett, A. A.; Harris, E.; Tristram, E. W.; Wyvratt, M. J.; Wu, M. T.; Taub, D.; Peterson, E. R.; Ikeler, T. J.; Broeke, J. T.; Payne, L. G.; Ondeyka, D. L.; Thorsett, E. D.; Greenlee, W. J.; Lohr, N. S.; Hoffsommer, R. D.; Joshua, H.; Ruyle, W. V.; Rothrock, J. W.; Aster, S. D.; Maycock, A. L.; Robinson, F. M.; Hirschmann, R. A new class of angiotensin-converting enzyme inhibitors. Nature 1980, 288, 280-283.
31. (31 ) Eddy, N. B.; Leimbach, D. Synthetic analgesia (II) diethylbutenyl and diethylbutylamines. J. Pharmacol. Exp. Ther. 1953, 107, 385-389.
32. Noble, F.; Soleilhac, J. M.; Soroca-Lucas, E.; Turcaud, S.; Fournié-Zaluski, M. C.; Roques, B. P. Inhibition of the enkephalin metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J. Pharmacol. Exp. Ther. 1992, 261, 181-190.
33. De Forrest, J. M.; Waldron, T. L.; Harvey, C.; Scalese, B.; Rubin, B.; Powell, J. R.; Petrillo, E. W.; Cushman, D. W. Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: In vitro and preclinical in vivo pharmacology. J. Cardiovasc. Pharmacol. 1989, 14, 730-736.
34. Curtius, T.; Sieber, W. Rearrangment of alkylmalonic acids in a-amino acids (Part II). Synthesis of β-phenyl-α-alanine and α-amino-n-butyric acid. Chem. Ber. 1922, 55B, 1543-1558.
35. Mannich, C.; Ritsert, K. About the condensation of malonic ester, diethylamine and formaldehyde. Chem. Ber. 1924, 57, 1116-1118.
36. Aubry, M.; Bertheloot, A.; Beaumont, A.; Roques, B. P.; Crine, P. The use of a monoclonal antibody for the high yield purification of kidney enkephalinase solubilized in β-octylglucoside. Biochem. Cell Biol. 1987, 65, 398-404.
37. Pantaliano, M. W.; Holmquist, B.; Riordan, J. F. Affinity Chromatographic purification of angiotensin converting enzyme. Biochemistry 1984, 23, 1037-1042.
38. 2)Phe-βAla, a specific fluorogenic substrate for neutral endopeptidase 24.11. Anal. Biochem. 1994, 219, 87-95.
39. Piquilloud, Y.; Reinharz, A.; Roth, M. Studies of the angiotensin converting enzyme with different substrates. Biochim. Biophys. Acta 1970, 206, 136-142.
40. Cheung, H. S.; Cushman, D. W. Inhibition of homogeneous angiotensin converting enzyme of rabbit lung by synthetic venom peptides of both rops jararaca. Biochim. Biophys. Acta 1973, 293, 451-457.
41. 50) of an enzyme reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
42. Haley, T. J.; McCormick, W. G. Pharmacological effects produced by intracerebroventricular injections of drugs in conscious mouse. Br. J. Pharmacol. 1957, 12, 12-16.
43. Litchfield, J. T.; Wilcoxon, F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949, 96, 99-113.